AU2019354714A1 - Humanised anti-N-truncated amyloid beta monoclonal antibody - Google Patents
Humanised anti-N-truncated amyloid beta monoclonal antibody Download PDFInfo
- Publication number
- AU2019354714A1 AU2019354714A1 AU2019354714A AU2019354714A AU2019354714A1 AU 2019354714 A1 AU2019354714 A1 AU 2019354714A1 AU 2019354714 A AU2019354714 A AU 2019354714A AU 2019354714 A AU2019354714 A AU 2019354714A AU 2019354714 A1 AU2019354714 A1 AU 2019354714A1
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- nt4x
- seq
- antibodies
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1816210.7 | 2018-10-04 | ||
| GB201816210 | 2018-10-04 | ||
| PCT/EP2019/076772 WO2020070225A1 (en) | 2018-10-04 | 2019-10-02 | Humanised anti-n-truncated amyloid beta monoclonal antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019354714A1 true AU2019354714A1 (en) | 2021-04-29 |
Family
ID=68136417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019354714A Pending AU2019354714A1 (en) | 2018-10-04 | 2019-10-02 | Humanised anti-N-truncated amyloid beta monoclonal antibody |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12297261B2 (https=) |
| EP (1) | EP3861023A1 (https=) |
| JP (1) | JP7610515B2 (https=) |
| KR (1) | KR102862077B1 (https=) |
| CN (1) | CN113056480B (https=) |
| AU (1) | AU2019354714A1 (https=) |
| BR (1) | BR112021006153A2 (https=) |
| CA (1) | CA3114669A1 (https=) |
| EA (1) | EA202190954A1 (https=) |
| IL (1) | IL281979B2 (https=) |
| MX (1) | MX2021003867A (https=) |
| SG (1) | SG11202102765RA (https=) |
| WO (1) | WO2020070225A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4118111A1 (en) | 2020-03-10 | 2023-01-18 | LifeArc | Cyclic peptides |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| PE20252307A1 (es) | 2022-12-22 | 2025-09-22 | Bioarctic Ab | Anticuerpo que se une a abetape3 |
| WO2025262228A1 (en) | 2024-06-20 | 2025-12-26 | Bioarctic Ab | Bispecific binding molecule |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US474900A (en) | 1892-05-17 | William byrnes | ||
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| WO2008081008A1 (en) * | 2007-01-05 | 2008-07-10 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
| MY155144A (en) | 2007-10-29 | 2015-09-15 | Inst Nat Sante Rech Med | NEW ANTIBODIES SPECIFIC OF THE ß-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS |
| WO2011151076A2 (en) * | 2010-06-04 | 2011-12-08 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS |
| EP2847217B1 (en) | 2012-05-10 | 2017-10-11 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST OLIGOMERS of Amyloid beta |
| WO2015173133A1 (en) | 2014-05-12 | 2015-11-19 | Chiesi Farmaceutici S.P.A. | Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy |
| CA2992386A1 (en) * | 2015-07-16 | 2017-01-19 | Probiodrug Ag | Humanized antibodies |
| CN111518206B (zh) * | 2019-02-01 | 2022-03-29 | 长春金赛药业有限责任公司 | 人源化抗Aβ单克隆抗体及其应用 |
| EP4118111A1 (en) * | 2020-03-10 | 2023-01-18 | LifeArc | Cyclic peptides |
-
2019
- 2019-10-02 BR BR112021006153-3A patent/BR112021006153A2/pt unknown
- 2019-10-02 CA CA3114669A patent/CA3114669A1/en active Pending
- 2019-10-02 KR KR1020217012796A patent/KR102862077B1/ko active Active
- 2019-10-02 IL IL281979A patent/IL281979B2/en unknown
- 2019-10-02 JP JP2021543565A patent/JP7610515B2/ja active Active
- 2019-10-02 SG SG11202102765RA patent/SG11202102765RA/en unknown
- 2019-10-02 EP EP19782593.8A patent/EP3861023A1/en active Pending
- 2019-10-02 AU AU2019354714A patent/AU2019354714A1/en active Pending
- 2019-10-02 US US17/282,592 patent/US12297261B2/en active Active
- 2019-10-02 CN CN201980065883.5A patent/CN113056480B/zh active Active
- 2019-10-02 WO PCT/EP2019/076772 patent/WO2020070225A1/en not_active Ceased
- 2019-10-02 EA EA202190954A patent/EA202190954A1/ru unknown
- 2019-10-02 MX MX2021003867A patent/MX2021003867A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3114669A1 (en) | 2020-04-09 |
| JP7610515B2 (ja) | 2025-01-08 |
| BR112021006153A2 (pt) | 2021-06-29 |
| MX2021003867A (es) | 2021-09-08 |
| JP2022513331A (ja) | 2022-02-07 |
| EA202190954A1 (ru) | 2021-06-29 |
| US20210347867A1 (en) | 2021-11-11 |
| EP3861023A1 (en) | 2021-08-11 |
| CN113056480A (zh) | 2021-06-29 |
| SG11202102765RA (en) | 2021-04-29 |
| KR102862077B1 (ko) | 2025-09-18 |
| IL281979B2 (en) | 2025-09-01 |
| KR20210080400A (ko) | 2021-06-30 |
| US12297261B2 (en) | 2025-05-13 |
| IL281979B1 (en) | 2025-05-01 |
| IL281979A (en) | 2021-05-31 |
| CN113056480B (zh) | 2025-06-13 |
| US20230203140A9 (en) | 2023-06-29 |
| WO2020070225A1 (en) | 2020-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240368263A1 (en) | Optimized anti-tl1a antibodies | |
| US12297261B2 (en) | Humanised anti-n-truncated amyloid β monoclonal antibody | |
| TWI823895B (zh) | 抗b7-h4抗體、其抗原結合片段及其醫藥用途 | |
| WO2018095428A1 (zh) | Cd47抗体、其抗原结合片段及其医药用途 | |
| KR20120075457A (ko) | 톨-유사 수용체 2에 대한 인간화 항체 및 이의 용도 | |
| BR112019025048A2 (pt) | anticorpo anti-cd40, fragmento de ligação ao antígeno do mesmo, e uso médico dos mesmos | |
| JP2025041747A (ja) | ヒト化抗ｉｌ１７ｂｒ抗体 | |
| TW201813979A (zh) | 抗ｃｄ２７抗體、其抗原結合片段及其醫藥用途 | |
| AU2019394099B2 (en) | Humanised anti-IL17BR antibody | |
| HK40042163A (en) | Optimized anti-tl1a antibodies |